The Reappearance of Procaine Hydrochloride (Gerovital H3) for Antiaging
clinical paper · 2013
LINK
SUMMARY
Modern editorial by the geriatrician Thomas T. Perls warning of a renewed marketing of Gerovital H3 / procaine for anti-aging, restating that there is no scientifically credible evidence that procaine hydrochloride benefits age-related disease and recounting the United States regulatory history (the US FDA's classification of Gerovital H3 as an unapproved new drug and its 1982 action against importation and anti-aging marketing). Citation metadata (author, title, journal, year, volume, issue, pages, PMID, DOI) copied from Crossref and PubMed on 2026-06-03 (Crossref: title 'The Reappearance of Procaine Hydrochloride (Gerovital H3) for Antiaging', author Perls, J Am Geriatr Soc 61(6):1024-1025, 2013, DOI 10.1111/jgs.12278; PubMed PMID 23772727).
NOTES
Perls’s 2013 Journal of the American Geriatrics Society editorial is the bundle’s modern anchor for both the evidentiary verdict and the United States regulatory status. It restates that no scientifically credible evidence supports procaine hydrochloride for age-related disease, and it sets out the FDA’s treatment of Gerovital H3 as an unapproved new drug (the 1982 action against its importation and anti-aging marketing), in the context of warning that the product was being marketed again.